Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedApr 02, 2026
DataAggregated Company Financials
Companies32
  • 7D1.0%
  • 3M-16.8%
  • 1Y-42.4%
  • YTDn/a

Over the last 7 days, the Biotech industry has remained flat, although notably Alterity Therapeutics gained 29%. Unfortunately though, the industry is down 42% over the past 12 months. As for the next few years, earnings are expected to grow by 30% per annum.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026AU$79.7bAU$23.7bAU$1.5b24.5x54.8x3.4x
Sat, 28 Feb 2026AU$81.9bAU$23.2bAU$1.5b25.7x56.4x3.5x
Mon, 26 Jan 2026AU$98.7bAU$23.8bAU$3.9b19.9x25.4x4.1x
Wed, 24 Dec 2025AU$97.3bAU$24.6bAU$4.0b18.9x24.3x4x
Fri, 21 Nov 2025AU$98.1bAU$25.4bAU$4.2b18.6x23.6x3.9x
Sun, 19 Oct 2025AU$119.2bAU$25.3bAU$4.1b22.9x28.8x4.7x
Tue, 16 Sep 2025AU$110.6bAU$24.7bAU$4.0b22x27.4x4.5x
Thu, 14 Aug 2025AU$142.9bAU$24.3bAU$3.8b43.6x37.3x5.9x
Sat, 12 Jul 2025AU$131.3bAU$24.2bAU$3.8b32.2x34.3x5.4x
Mon, 09 Jun 2025AU$131.3bAU$24.5bAU$3.9b20.5x33.9x5.4x
Wed, 07 May 2025AU$136.5bAU$24.6bAU$3.9b21.5x35.1x5.5x
Fri, 04 Apr 2025AU$138.9bAU$25.1bAU$4.0b21.4x35x5.5x
Sun, 02 Mar 2025AU$142.0bAU$25.6bAU$4.1b21.6x35x5.6x
Tue, 28 Jan 2025AU$148.2bAU$24.4bAU$3.7b24.2x40.5x6.1x
Thu, 26 Dec 2024AU$150.8bAU$24.7bAU$3.7b24.5x40.9x6.1x
Sat, 23 Nov 2024AU$146.7bAU$23.7bAU$3.5b25.6x41.7x6.2x
Mon, 21 Oct 2024AU$158.4bAU$23.0bAU$3.4b28.2x46.6x6.9x
Wed, 18 Sep 2024AU$154.2bAU$22.8bAU$3.4b29x45.7x6.8x
Fri, 16 Aug 2024AU$156.1bAU$23.2bAU$3.5b29.8x44.3x6.7x
Sun, 14 Jul 2024AU$160.1bAU$21.8bAU$3.2b33.3x50.3x7.4x
Tue, 11 Jun 2024AU$150.7bAU$22.4bAU$3.3b31.1x45.8x6.7x
Thu, 09 May 2024AU$145.1bAU$22.4bAU$3.3b30.8x44.3x6.5x
Sat, 06 Apr 2024AU$144.1bAU$22.3bAU$3.3b31.3x44.1x6.5x
Mon, 04 Mar 2024AU$143.9bAU$22.5bAU$3.3b29.6x43.7x6.4x
Wed, 31 Jan 2024AU$150.9bAU$20.8bAU$2.8b34.2x54.7x7.3x
Fri, 29 Dec 2023AU$145.7bAU$20.1bAU$2.6b34.8x55.1x7.3x
Sun, 26 Nov 2023AU$131.4bAU$20.8bAU$2.8b32.4x47.4x6.3x
Tue, 24 Oct 2023AU$120.4bAU$21.7bAU$2.9b29.1x41.3x5.5x
Thu, 21 Sep 2023AU$134.3bAU$21.2bAU$2.8b31.2x48.4x6.3x
Sat, 19 Aug 2023AU$138.3bAU$21.3bAU$2.6b38.3x54x6.5x
Mon, 17 Jul 2023AU$135.5bAU$17.6bAU$2.3b36.9x59.9x7.7x
Wed, 14 Jun 2023AU$157.6bAU$17.8bAU$2.3b41.5x69x8.9x
Fri, 12 May 2023AU$155.0bAU$17.8bAU$2.3b41.7x67.5x8.7x
Sun, 09 Apr 2023AU$153.0bAU$18.0bAU$2.3b41x65.8x8.5x
Price to Earnings Ratio

65.8x


Total Market Cap: AU$153.0bTotal Earnings: AU$2.3bTotal Revenue: AU$18.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 43.4x202420252026
Current Industry PE
  • Investors are optimistic on the Australian Biotechnology industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 54.8x which is higher than its 3-year average PE of 43.4x.
  • The 3-year average PS ratio of 6.0x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have declined 15% per year over the last three years.
  • Meanwhile revenues for these companies have grown 9.6% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Australian Biotech compare with similar industries?

AU Market1.39%
Healthcare1.49%
Biotech0.99%
Biotech0.99%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ATH Alterity TherapeuticsAU$0.00928.6%
+AU$21.8m		12.5%PS14.7x
TLX Telix PharmaceuticalsAU$12.950.2%
+AU$10.2m		-49.3%PS3.7x
NSB NeuroScientific BiopharmaceuticalsAU$0.1033.3%
+AU$8.3m		156.4%PS104.6x
OCC OrthocellAU$0.813.9%
+AU$8.1m		-43.9%PS23.4x
COV Cleo DiagnosticsAU$0.567.8%
+AU$5.5m		50.0%PS29.6x

Latest News

TLX
AU$12.95
Telix Pharmaceuticals
7D
0.2%
1Y
-49.3%
ACW
AU$0.037
Actinogen Medical
7D
2.8%
1Y
8.8%
ATX
AU$0.24
Amplia Therapeutics
7D
4.3%
1Y
269.2%

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Mar 31
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
ATH
AU$0.009
Alterity Therapeutics
7D
28.6%
1Y
12.5%
PYC
AU$1.12
PYC Therapeutics
7D
-4.7%
1Y
-3.0%
CUV
AU$9.02
Clinuvel Pharmaceuticals
7D
-7.8%
1Y
-17.6%

CUV: Stable Fair Value With Stronger Margins Will Support Future Upside Potential

Analysts have kept their A$13.00 price target for Clinuvel Pharmaceuticals unchanged, pointing to largely stable fair value assumptions with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E inputs. Valuation Changes Fair Value: A$13.00 fair value estimate is unchanged.
CSL
AU$138.93
CSL
7D
-3.8%
1Y
-46.1%

CSL: Manufacturing Expansion And Horizon 2 Rollout Will Support Future Share Recovery

Narrative Update on CSL Analysts have adjusted CSL's fair value estimate from A$205.16 to A$207.81. This reflects updated views on its discount rate, revenue growth, profit margins and future P/E assumptions, alongside recent mixed rating actions on the stock.
IMM
AU$0.044
Immutep
7D
-4.3%
1Y
-83.1%
CMB
AU$0.41
Cambium Bio
7D
-14.6%
1Y
43.9%
TTX
AU$4.34
Tetratherix
7D
-6.1%
1Y
n/a
MSB
AU$2.13
Mesoblast
7D
-2.7%
1Y
13.6%
NXN
AU$0.20
Nexsen
7D
14.7%
1Y
n/a
OCC
AU$0.81
Orthocell
7D
3.9%
1Y
-43.9%
RAC
AU$2.63
Racura Oncology
7D
-2.6%
1Y
127.7%
NSB
AU$0.10
NeuroScientific Biopharmaceuticals
7D
33.3%
1Y
156.4%
COV
AU$0.56
Cleo Diagnostics
7D
7.8%
1Y
50.0%